| AstraZeneca AG - Saphnelo 300 mg/2 ml, Konzentrat zur Herstellung einer Infusionslösung |
| 68512 | | 01 | | Saphnelo 300 mg/2 ml | | Konzentrat zur Herstellung einer Infusionslösung | | L04AG11 | | | | 31.08.2022 | | |
|
| Composition |
| anifrolumabum 300 mg, histidinum, histidini hydrochloridum monohydricum, lysini hydrochloridum, trehalosum dihydricum, polysorbatum 80, aqua ad iniectabile q.s. ad solutionem pro 2 ml. |
| Packungsbestandteile |
| Concentrate for infusion | | | | | | | | Active Agent | Dose |
|---|
| Anifrolumabum | 300mg / 2ml |
| | BAG: Active Agent | Dose |
|---|
| Anifrolumabum | 300 mg |
| | | | Inactive agents |
|---|
| Histidin Hydrochloride Monohydrate | | Histidine | | Lysine Hydrochloride | | Polysorbatum 80 | | Trehalosum Dihydricum |
| |
|
| Package number | Package Size | EFP | CP | Category | SL | Out of trade (MedRef) |
|---|
| 001 | | 895.73 | 990.60 | A | SL | Yes |
|
